Trial Details
TERMINATEDBasic Information
| Clinical ID | c2053 |
|---|---|
| Identifier | NCT04043455 |
| Trial Title | Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Irritable Bowel Syndrome |
| Interventions | DRUG: Olorinab|DRUG: Olorinab|DRUG: Olorinab|DRUG: Placebo|DRUG: Olorinab|DRUG: Olorinab |
Participant Information
| Sponsor | Arena Pharmaceuticals |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2019-07-24 |
|---|---|
| Primary Completion Date | 2021-04-29 |
| Completion Date | 2021-04-29 |